Ascendis Pharma A/S (ASND) News Today $161.57 +1.24 (+0.77%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tema Etfs LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Tema Etfs LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,040 shares of the biotechnology company's stock, valuMay 20 at 6:16 AM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of "Buy" from BrokeragesMay 19 at 3:31 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have earned a consensus recommendation of "Buy" from the fifteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation. The average 12-month price oMay 16, 2025 | marketbeat.comMaven Securities LTD Sells 40,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Maven Securities LTD decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,000 shares of the biotechnology company's stock after sellingMay 15, 2025 | marketbeat.comMoore Capital Management LP Cuts Position in Ascendis Pharma A/S (NASDAQ:ASND)Moore Capital Management LP decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 50.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,000 shares of the biotechnology company's stock after selling 20,000 shaMay 15, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases New Position in Ascendis Pharma A/S (NASDAQ:ASND)Balyasny Asset Management L.P. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,419 shares of the biotechnology compMay 15, 2025 | marketbeat.comAscendis Pharma Announces Long-Term Phase 2 Trial Data Demonstrating Sustained Efficacy and Safety of TransCon PTH in Adults with HypoparathyroidismMay 14, 2025 | nasdaq.comAscendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday.May 14, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives "Overweight" Rating from Cantor FitzgeraldMay 14, 2025 | americanbankingnews.comAscendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long TermMay 13, 2025 | insidermonkey.comNew Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)May 13, 2025 | globenewswire.comJanus Henderson Group PLC Purchases 193,688 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,380,382 shares of the biotechnology companMay 13, 2025 | marketbeat.comAscendis Pharma: New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 13, 2025 | finanznachrichten.deNew 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 12, 2025 | globenewswire.comDriehaus Capital Management LLC Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Driehaus Capital Management LLC reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 22.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,496 shares of the biotechnology company's stockMay 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stake Lessened by Fred Alger Management LLCFred Alger Management LLC reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 56.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,854 shares of the biotechnology coMay 11, 2025 | marketbeat.comCantor Fitzgerald Has Weak Outlook for ASND FY2025 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Ascendis Pharma A/S in a research note issued to investors on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology companMay 10, 2025 | marketbeat.comMorgan Stanley Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to "Overweight"Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $180.00 to $250.00 in a research report on Monday.May 7, 2025 | marketbeat.comBellevue Group AG Takes $344,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)Bellevue Group AG acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,500 shares of the biotechnology company's stock, valued at approximatelyMay 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires 40,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Alyeska Investment Group L.P. increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 34.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 155,000 shares of the biotechnology company's stock after buying an additional 40,000 shares duriMay 7, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Boosts Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)The Manufacturers Life Insurance Company grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,955 shares of the biotechnologyMay 7, 2025 | marketbeat.comStifel Financial Corp Has $2.35 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Stifel Financial Corp boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 36.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,097 shares of the biotechnology company's stock after pMay 7, 2025 | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for ASNDAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Wedbush boosted their FY2029 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, May 1st. Wedbush analyst Y. Zhong now anticipates that the biotechnMay 7, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 YearsMay 7, 2025 | benzinga.comLaunch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1May 7, 2025 | msn.comAquatic Capital Management LLC Takes $230,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)Aquatic Capital Management LLC acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,674 shares of the biotechnology company's sMay 6, 2025 | marketbeat.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025May 5, 2025 | finance.yahoo.comMorgan Stanley Upgrades Ascendis Pharma A (ASND)May 5, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Releases Earnings Results, Misses Expectations By $0.10 EPSAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million.May 5, 2025 | marketbeat.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025May 5, 2025 | globenewswire.comAristeia Capital L.L.C. Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Aristeia Capital L.L.C. bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,800 shares of the biotechnology company's stock, valued at approximately $1,487,000. OtherMay 5, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 4, 2025 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Evercore ISI Analyst SaysEvercore ISI lifted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday.May 4, 2025 | marketbeat.comAcuta Capital Partners LLC Grows Stake in Ascendis Pharma A/S (NASDAQ:ASND)Acuta Capital Partners LLC lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 9.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,976 shares of the biotechnology company's stock after buying aMay 4, 2025 | marketbeat.comRA Capital Management L.P. Buys 402,316 Shares of Ascendis Pharma A/S (NASDAQ:ASND)RA Capital Management L.P. grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,112,744 shares of the biotechnology company's stock after acquiring an adMay 3, 2025 | marketbeat.comAscendis Pharma’s Earnings Call: Growth Amid ChallengesMay 2, 2025 | tipranks.comAscendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call TranscriptMay 2, 2025 | msn.comSchonfeld Strategic Advisors LLC Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Schonfeld Strategic Advisors LLC cut its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 39.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 138,593 shares oMay 2, 2025 | marketbeat.comEnvestnet Asset Management Inc. Cuts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)Envestnet Asset Management Inc. trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,577 shares of the biotechnology company's stockMay 2, 2025 | marketbeat.comQ1 2025 Ascendis Pharma A/S Earnings Call TranscriptMay 2, 2025 | gurufocus.comAscendis Pharma A/S (ASND) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comAscendis Pharma Reports Q1 2025 Financial Results with Improved LossesMay 1, 2025 | tipranks.comAscendis Pharma Reports First Quarter 2025 Financial ResultsMay 1, 2025 | globenewswire.comA Glimpse of Ascendis Pharma's Earnings PotentialMay 1, 2025 | benzinga.comAscendis Pharma A/S (NASDAQ:ASND) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 7.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,283,207 shares of the biotechnologyApril 28, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Trading 4.4% Higher - Still a Buy?Ascendis Pharma A/S (NASDAQ:ASND) Trading 4.4% Higher - Time to Buy?April 27, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Legal & General Group PlcLegal & General Group Plc increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1,577.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,682 shares of the biotechnology company's stApril 27, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. increased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,725,546 shares ofApril 26, 2025 | marketbeat.comAscendis Pharma A/S (ASND) to Release Earnings on ThursdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-ascendis-pharma-as-stock/)April 26, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Guggenheim Capital LLCGuggenheim Capital LLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 256.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,249 shares of the biotechnology company's stock after purchasing an additional 5,218 shares during tApril 25, 2025 | marketbeat.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼1.020.65▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼97▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARGX News Today BNTX News Today ONC News Today TEVA News Today SMMT News Today ITCI News Today GMAB News Today RDY News Today VTRS News Today MRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASND Stock Free ASND Stock Alerts